Limited Competition RFA for the IARC Monographs for the Evaluation of Carcinogenic Risks to Humans

Ron Johnson, PhD Program Director Division of Cancer Biology

Purpose

- Limited competition RFA for the Monograph program at the International Agency for Research on Cancer (IARC)
- IARC Monographs- critical scientific evaluations of carcinogenic hazards to humans
- NCI support since 1982 via an U01 award
- IARC award not previously associated with a funding announcement but is now required
- This RFA will enable submission of a renewal application

IARC Monograph Process

- Types of agents considered
 - Chemicals and chemical mixtures
 - Physical and biological agents
 - Occupational exposures and lifestyle factors
- Prioritized by Advisory Group
- Criteria
 - Extent of human exposure
 - Suspicion of carcinogenicity
 - Public health relevance or public concern
 - New or unpublished studies

IARC Monograph Process

- Working Group reviews literature comprehensively
 - Exposure data
 - Cancer epidemiology studies
 - Cancer bioassays in animals
 - Mechanistic data
- Determination based on weight of evidence
- Three Working Groups per year (NCI funds two)
- Volumes freely available as PDFs

Agents Evaluated or Planned

- High concern
 - Shift work, Radiofrequency EMFs, Motor vehicle exhaust
- Global/Low-Middle Income Countries
 - Indoor combustion/cooking, Schistosoma haematobium, Areca nut, Chinese-style salted fish
- New & high priority for 2015-2019
 - Bisphenol A, Aspartame, Indium tin oxide,
 Nicotine/e-cigarettes

IARC Monograph Program

- Authoritative- used by health agencies and institutions world wide
- Well respected- high scientific rigor, independence, and transparency
- Relevant- considers agents of current wide exposure or of high public concern
- Global- evaluates agents of international concern
- Over 900 agents evaluated by 109 Working Groups

Portfolio Analysis

- Unique NIH award
- US carcinogen identification programs
 - Report on Carcinogens (NTP, NIEHS)
 - Integrated Risk Information System (EPA)
- IARC contrasts
 - Broader number and type of agents evaluated
 - Agents of global concern, especially LMICs
 - Frequently the first to evaluate an agent
- IARC complements
 - Involves US agencies (EPA, NIH, CDC) in evaluations and exchange of information

FOA Justification

- RFA
 - Limited competition- uniquely positioned institution
 - Review by NCI special emphasis panel
- U01 (NCI interaction)
 - Recommend agents for evaluation
 - Identify resource individuals in US
 - Attend or participate in Working Group meetings

Requested Set Aside

- \$859,000 TC/year for 5 years
- \$4,295,000 total
- Based on current award
- Allocation
 - IARC personnel 80%
 - Convening Working Groups 20%

IARC vs Report on Carcinogens

IARC

Risk to Humans	# Agents
Carcinogenic	113
Probably carcinogenic	66
Possibly carcinogenic	285
Not classifiable	505
Probably not carcinogenic	1

Report on Carcinogens

Carcinogenicity	# Agents
Known	54
Reasonably suspected	186